Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
| ▸ | CDK2AP2 | O75956 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772584 | 0.94 | TERT (0.35) | IGF1RCYP3A4NTRK1ACVRL1 | |
| SCHEMBL772509 | 0.85 | PARP1 (0.36) | IGF1RCYP3A4HTR4CDK2AP2EGFR | |
| SCHEMBL773097 | 0.81 | PARP1 (0.34) | IGF1RCYP3A4NTRK1ACVRL1PARP1 | |
| SCHEMBL773254 | 0.78 | NTRK1 (0.45) | IGF1RCYP3A4HTR4CDK2AP2EGFR | |
| SCHEMBL772905 | 0.77 | NTRK1 (0.49) | IGF1RCYP3A4EGFRNTRK1ACVRL1 | |
| SCHEMBL772497 | 0.77 | NTRK1 (0.41) | IGF1RCYP3A4CDK2AP2EGFRERBB2 | |
| SCHEMBL10283981 | 0.72 | NTRK1 (0.46) | IGF1RMETKDRNTRK1ACVRL1 | |
| SCHEMBL772913 | 0.70 | NTRK1 (0.42) | IGF1RCYP3A4CDK2AP2EGFRERBB2 | |
| SCHEMBL772581 | 0.70 | NTRK1 (0.49) | IGF1RCYP3A4NTRK1ACVRL1PARP1 | |
| SCHEMBL10283983 | 0.70 | NTRK1 (0.46) | HTR4METKDRNTRK1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | IGF1R 2381/4885CYP3A4 1201/4885HTR4 4128/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | IGF1R 2381/4885CYP3A4 1201/4885HTR4 4128/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | IGF1R 2381/4885CYP3A4 1201/4885HTR4 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.